CDTX CIDARA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended September 30, 2025, CIDARA THERAPEUTICS INC reported revenue of $0, net income of −$83.2M and diluted EPS of −$3.10; over the last four quarters revenue was $0 and net income −$185M; for the fiscal year ended December 2024 revenue was $1.28M, down 94.5% on the year before.
CDTX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $1.28M, gross profit n/a, operating income −$176M, net income −$170M (margin -13319.8%), EPS −$26.75
- Fiscal year ended Dec 2023: revenue $23.3M, gross profit n/a, operating income −$27.1M, net income −$22.9M (margin -98.5%), EPS −$5.25
- Fiscal year ended Dec 2022: revenue $64.4M, gross profit n/a, operating income −$33.5M, net income −$33.6M (margin -52.1%), EPS −$0.48
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$42.3M, net income −$42.5M (margin n/a), EPS −$0.81
CDTX quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $0, net income −$83.2M, EPS −$3.10
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$25.7M, EPS −$1.65
- Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$23.5M, EPS −$1.66
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (up 100.0% year over year), net income −$52.3M, EPS −$2.03
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$16.0M, EPS −$2.45
- Quarter ended Jun 30, 2024: revenue $302K (down 94.1% year over year), net income −$91.2M, EPS −$19.99
- Quarter ended Mar 31, 2024: revenue $973K (down 96.3% year over year), net income −$10.3M, EPS −$2.28
- Quarter ended Dec 31, 2023 (from the annual report): revenue −$17.1M (down 267.6% year over year), net income −$3.21M, EPS −$0.81
- Quarter ended Sep 30, 2023: revenue $9.22M (down 77.4% year over year), net income −$9.11M, EPS −$2.02
- Quarter ended Jun 30, 2023: revenue $5.09M (down 18.1% year over year), net income −$13.6M, EPS −$3.02
- Quarter ended Mar 31, 2023: revenue $26.1M (up 259.2% year over year), net income $3.01M, EPS $0.60
- Quarter ended Dec 31, 2022 (from the annual report): revenue $10.2M, net income −$13.6M, EPS −$0.14
- Quarter ended Sep 30, 2022: revenue $40.7M, net income $14.2M, EPS $0.16
- Quarter ended Jun 30, 2022: revenue $6.22M, net income −$15.8M, EPS −$0.23
- Quarter ended Mar 31, 2022: revenue $7.27M, net income −$18.5M, EPS −$0.27
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$16.8M, EPS −$0.23
- Quarter ended Sep 30, 2021: revenue n/a, net income −$18.1M, EPS −$0.37
- Quarter ended Jun 30, 2021: revenue n/a, net income $10.7M, EPS $0.18
- Quarter ended Mar 31, 2021: revenue n/a, net income −$18.3M, EPS −$0.39
CDTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$177M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$22.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$28.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$25.2M, share buybacks n/a
CDTX balance sheet
- Sep 30, 2025: cash $294M, total assets $519M, total liabilities $96.3M, shareholders' equity $422M
- Jun 30, 2025: cash $511M, total assets $534M, total liabilities $33.2M, shareholders' equity $501M
- Mar 31, 2025: cash $168M, total assets $192M, total liabilities $50.0M, shareholders' equity $142M
- Dec 31, 2024: cash $190M, total assets $215M, total liabilities $51.5M, shareholders' equity $163M
- Sep 30, 2024: cash $127M, total assets $162M, total liabilities $46.7M, shareholders' equity $116M
- Jun 30, 2024: cash $164M, total assets $173M, total liabilities $42.4M, shareholders' equity $131M
- Mar 31, 2024: cash $29.0M, total assets $52.7M, total liabilities $70.5M, shareholders' equity −$17.8M
- Dec 31, 2023: cash $35.8M, total assets $67.0M, total liabilities $75.2M, shareholders' equity −$8.21M
What is CDTX's revenue?
CIDARA THERAPEUTICS INC reported $0 of revenue over its last four quarters, through September 30, 2025.
Is CDTX profitable?
No. CIDARA THERAPEUTICS INC lost $185M over the last four quarters.
What is CDTX's EPS?
Diluted earnings per share over the last four quarters were −$8.44; −$3.10 in the latest quarter.